STAT News · Scour

STAT+: Pharmalittle: We’re reading about Trump and drug prices, biotechs pushing back, and more

statnews.com·9w

Make next year’s flu shots, says FDA committee

statnews.com·9w

STAT+: Trump is getting more credit than Biden for efforts to lower drug prices

statnews.com·9w

Opinion: America has health alarm fatigue. I know because I treat it

statnews.com·9w

FDA move on flavored vapes rattles public health experts

statnews.com·9w

STAT+: Leapfrog Group’s legal defeat underscores challenges of rating hospital quality

statnews.com·9w

STAT+: White House says it’s ‘done’ with vaccines. MAHA begs to differ

statnews.com·9w

Opinion: STAT+: How surrealism helps us make sense of and live with dementia

statnews.com·9w

STAT+: Congressional advisers call to rein in Medicare Advantage spending amid industry pressure

statnews.com·9w

STAT+: Cancer cells can ‘barf’ proteins onto their cell surface. That may create new targets for immunotherapies

statnews.com·9w

Epstein’s pal attempts a biotech comeback, and Prasad exits the FDA

statnews.com·9w

STAT+: FDA launches unified system for adverse event reports

statnews.com·9w

Analysis of Medicare data shows who mental health providers treat over telehealth

statnews.com·9w

STAT+: Pharmalittle: We’re reading about telehealth prescribers, a Lilly push against compounding, and more

statnews.com·9w

An NIH whistleblower warning

statnews.com·9w

STAT+: Is Aldeyra Therapeutics waving red flags with consequences?

statnews.com·9w

Momentum builds for a federal office of men’s health focused on disease prevention

statnews.com·9w

STAT+: The FDA is targeting telehealth marketing of GLP-1 drugs. Who’s prescribing them?

statnews.com·9w

Opinion: I’m an NIH whistleblower. The scientific community cannot afford to avoid politics

statnews.com·9w

Opinion: STAT+: It’s the 50th anniversary of the U.S. biotech industry. What will the next 50 years look like?

statnews.com·9w

Log in to enable infinite scrolling